4.7 Article

Hyaluronic acid/Chitosan nanoparticles as delivery vehicles for VEGF and PDGF-BB

期刊

DRUG DELIVERY
卷 17, 期 8, 页码 596-604

出版社

TAYLOR & FRANCIS LTD
DOI: 10.3109/10717544.2010.509357

关键词

Nanoparticles; hyaluronic acid; chitosan; tissue engineering; angiogenesis; growth factors

资金

  1. European Community [VASCUPLUG NMP3-CT-2005-013811]
  2. Spanish Ministry of Science and Technology [CSD2006-00012]
  3. Xunta de Galicia [PGIDIT07PXIB203067PR]
  4. Xunta de Galicia

向作者/读者索取更多资源

The development of a vascular network in tissue-engineered constructs is a fundamental bottleneck of bioregenerative medicine, particularly when the size of the implant exceeds a certain limit given by diffusion lengths and/or if the host tissue shows a very active metabolism. One of the approaches to achieve the vascularization of tissue constructs is generating a sustained release of proangiogenic factors from the ischemic site. This work describes the formation and characterization of hyaluronic acid-chitosan (HA/CS) nanoparticles for the delivery of two pro-angiogenic growth factors: vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF-BB). These nanoparticles were prepared by an ionic gelification technique, and different formulations were developed by encapsulating the growth factors in association with two stabilizing agents: bovine serum albumin or heparin sodium salt. These carriers were characterized with regard to their physicochemical properties, their stability in biological media, and their cytotoxicity in the C3a hepatoma cell line. The results show that nanoparticles around 200 nm can be prepared by this method. HA/CS nanoparticles were stable when incubated in EMEM cell culture medium or in water at 37 degrees C for 24 h. Cell culture tests confirmed that HA/CS nanoparticles are not cytotoxic within the concentration range used for growth factor delivery. Moreover, HA/CS nanoparticles were able to entrap efficiently both growth factors, reaching association values of 94% and 54% for VEGF and PDGF, respectively. In vitro release studies confirm that PDGF-BB is released from HA/CS nanoparticles in a sustained manner over similar to 1 week. On the other hand, VEGF is completely released within the first 24 h.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据